Ann: Security Class Reinstatement to Quotation- OPTOB, page-561

Thanks primaus, sounds like it could be what's playing out.

It will be interesting to see how it all plays out. Hopefully the conversion of options on a positive readout means they don't have to do another CR.

I can't help but think a strong readout of 5+ letters from the COAST trial will lead to a significant T/O offer prior to SHORE.

I presume in the event of a T/O, the acquiring pharma would buy the options at the SP offer less conversion price?